About Integra LifeSciences Holdings Corporation (NASDAQ:IART)
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:IART
- CUSIP: 45798520
- Web: www.integralife.com
Capitalization:- Market Cap: $3.86722 billion
- Outstanding Shares: 78,078,000
Average Prices:- 50 Day Moving Avg: $50.58
- 200 Day Moving Avg: $49.61
- 52 Week Range: $37.71 - $56.42
P/E:- Trailing P/E Ratio: 61.70
- Foreward P/E Ratio: 21.44
- P/E Growth: 2.32
Sales & Book Value:- Annual Revenue: $1.05 billion
- Price / Sales: 3.76
- Book Value: $11.55 per share
- Price / Book: 4.38
Profitability:- EBITDA: $240.98 million
- Net Margins: 6.27%
- Return on Equity: 16.79%
- Return on Assets: 7.35%
Debt:- Debt-to-Equity Ratio: 0.97%
- Current Ratio: 3.46%
- Quick Ratio: 2.14%
Misc:- Average Volume: 566,150 shs.
- Beta: 0.71
- Short Ratio: 6.29
Frequently Asked Questions for Integra LifeSciences Holdings Corporation (NASDAQ:IART)
What is Integra LifeSciences Holdings Corporation's stock symbol?
Integra LifeSciences Holdings Corporation trades on the NASDAQ under the ticker symbol "IART."
When did Integra LifeSciences Holdings Corporation's stock split? How did Integra LifeSciences Holdings Corporation's stock split work?
Integra LifeSciences Holdings Corporation shares split on the morning of Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly created shares were distributed to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of Integra LifeSciences Holdings Corporation stock prior to the split would have 200 shares after the split.
How were Integra LifeSciences Holdings Corporation's earnings last quarter?
Integra LifeSciences Holdings Corporation (NASDAQ:IART) posted its earnings results on Wednesday, July, 26th. The company reported $0.45 earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of $0.45. The business had revenue of $282.16 million for the quarter, compared to analysts' expectations of $283.58 million. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The company's revenue for the quarter was up 13.2% on a year-over-year basis. During the same quarter last year, the business posted $0.40 EPS. View Integra LifeSciences Holdings Corporation's Earnings History.
When will Integra LifeSciences Holdings Corporation make its next earnings announcement?
What guidance has Integra LifeSciences Holdings Corporation issued on next quarter's earnings?
Integra LifeSciences Holdings Corporation issued an update on its FY17 earnings guidance on Wednesday, July, 26th. The company provided earnings per share (EPS) guidance of $1.88-1.94 for the period, compared to the Thomson Reuters consensus estimate of $1.92. The company issued revenue guidance of $1.125-1.14 billion, compared to the consensus revenue estimate of $1.13 billion.
Where is Integra LifeSciences Holdings Corporation's stock going? Where will Integra LifeSciences Holdings Corporation's stock price be in 2017?
9 brokerages have issued twelve-month target prices for Integra LifeSciences Holdings Corporation's stock. Their predictions range from $46.00 to $65.00. On average, they anticipate Integra LifeSciences Holdings Corporation's share price to reach $53.56 in the next year. View Analyst Ratings for Integra LifeSciences Holdings Corporation.
Who are some of Integra LifeSciences Holdings Corporation's key competitors?
Some companies that are related to Integra LifeSciences Holdings Corporation include STERIS PLC (STE), West Pharmaceutical Services (WST), Bio-Rad Laboratories (BIO), Hill-Rom Holdings (HRC), VWR Corporation (VWR), DexCom (DXCM), ICU Medical (ICUI), LivaNova PLC (LIVN), Neogen Corporation (NEOG), NuVasive (NUVA), Nevro Corp. (NVRO), Haemonetics Corporation (HAE), Halyard Health (HYH), Inogen (INGN), MiMedx Group (MDXG), CONMED Corporation (CNMD), Asante Solutions (PUMP) and OraSure Technologies (OSUR).
Who are Integra LifeSciences Holdings Corporation's key executives?
Integra LifeSciences Holdings Corporation's management team includes the folowing people:
- Stuart M. Essig Ph.D., Independent Chairman of the Board
- Peter J. Arduini, President, Chief Executive Officer, Director
- Glenn G. Coleman, Chief Financial Officer, Principal Accounting Officer, Corporate Vice President
- Lisa Evoli, Corporate Vice President, Chief Human Resources Officer
- Kenneth Burhop Ph.D., Chief Scientific Officer, Corporate Vice President
- John Mooradian, Corporate Vice President - Global Operations and Supply Chain
- Richard D. Gorelick, Corporate Vice President, General Counsel, Administration, Secretary
- Robert T. Davis Jr., Corporate Vice President, President — Specialty Surgical Solutions
- Judith E. O'Grady R.N., Corporate Vice President - Global Regulatory Affairs
- Daniel L. Reuvers, Corporate Vice President, President - Specialty Surgical Solutions
How do I buy Integra LifeSciences Holdings Corporation stock?
Shares of Integra LifeSciences Holdings Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Integra LifeSciences Holdings Corporation's stock price today?
One share of Integra LifeSciences Holdings Corporation stock can currently be purchased for approximately $50.59.
MarketBeat Community Rating for Integra LifeSciences Holdings Corporation (NASDAQ IART)MarketBeat's community ratings are surveys of what our community members think about Integra LifeSciences Holdings Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Integra LifeSciences Holdings Corporation (NASDAQ:IART) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 7 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.78) |
| Consensus Price Target: | $53.56 (5.86% upside) |
Consensus Price Target History for Integra LifeSciences Holdings Corporation (NASDAQ:IART)
Analysts' Ratings History for Integra LifeSciences Holdings Corporation (NASDAQ:IART)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/12/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $58.00 | N/A |  |
| 9/18/2017 | Oppenheimer Holdings, Inc. | Reiterated Rating | Buy | $60.00 | Low | |
| 9/12/2017 | Barclays PLC | Reiterated Rating | Equal Weight | $47.00 -> $53.00 | High | |
| 7/27/2017 | Raymond James Financial, Inc. | Boost Price Target | Outperform | $51.00 -> $55.00 | Low | |
| 7/26/2017 | Cantor Fitzgerald | Set Price Target | Buy | $65.00 | Low | |
| 5/2/2017 | Royal Bank Of Canada | Reiterated Rating | Sector Perform -> Sector Perform | $46.00 -> $48.00 | Low | |
| 3/22/2017 | Piper Jaffray Companies | Reiterated Rating | Overweight | $47.00 | Low | |
| 1/6/2017 | JMP Securities | Upgrade | Market Perform -> Outperform | $50.00 | N/A | |
| 10/28/2016 | Lake Street Capital | Upgrade | Hold -> Buy | $46.00 | N/A | |
| 9/23/2016 | Argus | Boost Price Target | Buy | $45.00 -> $52.50 | N/A | |
| 7/13/2016 | J P Morgan Chase & Co | Initiated Coverage | Overweight | | N/A | |
| 11/12/2015 | Citigroup Inc. | Initiated Coverage | Buy | $37.50 | N/A | |
(Data available from 10/19/2015 forward)
Earnings History for Integra LifeSciences Holdings Corporation (NASDAQ:IART)Earnings History by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ IART)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/26/2017 | | $0.47 | | | | | N/A | |
| 7/26/2017 | Q2 2017 | $0.45 | $0.45 | $283.58 million | $282.16 million | View | N/A | |
| 4/26/2017 | Q1 17 | $0.40 | $0.39 | $254.19 million | $258.60 million | View | N/A | |
| 2/23/2017 | Q4 2016 | $0.52 | $0.52 | $257.27 million | $255.70 million | View | N/A | |
| 10/27/2016 | Q3 | $0.89 | $0.93 | $249.30 million | $250.30 million | View | Listen | |
| 7/28/2016 | Q216 | $0.76 | $0.79 | $243.17 million | $249.30 million | View | Listen | |
| 4/27/2016 | Q116 | $0.73 | $0.74 | $230.66 million | $236.80 million | View | Listen | |
| 2/25/2016 | Q4 | $0.86 | $0.87 | $241.11 million | $241.20 million | View | Listen | |
| 11/3/2015 | Q315 | $0.74 | $0.75 | $224.08 million | $226.40 million | View | Listen | |
| 7/30/2015 | Q215 | $0.73 | $0.79 | $239.91 million | $244.10 million | View | Listen | |
| 4/30/2015 | Q115 | $0.63 | $0.76 | $229.69 million | $233.70 million | View | N/A | |
| 2/24/2015 | Q414 | $0.89 | $0.94 | $244.39 million | $252.20 million | View | Listen | |
| 11/3/2014 | Q314 | $0.74 | $0.76 | $233.50 million | $229.70 million | View | Listen | |
| 8/5/2014 | Q214 | $0.63 | $0.68 | $229.32 million | $231.40 million | View | N/A | |
| 5/1/2014 | Q114 | $0.58 | $0.57 | $213.30 million | $215.00 million | View | N/A | |
| 2/25/2014 | Q413 | $0.81 | $0.78 | $223.37 million | $220.80 million | View | N/A | |
| 10/28/2013 | Q313 | $0.70 | $0.72 | $214.05 million | $213.20 million | View | N/A | |
| 8/1/2013 | Q2 2013 | $0.55 | $0.60 | $207.30 million | $205.50 million | View | N/A | |
| 5/2/2013 | Q1 2013 | $0.37 | $0.39 | $195.20 million | $196.70 million | View | N/A | |
| 2/21/2013 | Q4 2012 | $0.76 | $0.78 | $215.90 million | $214.40 million | View | N/A | |
| 10/24/2012 | | $0.77 | $0.85 | | | View | N/A | |
| 7/26/2012 | | $0.69 | $0.74 | | | View | N/A | |
| 4/25/2012 | | $0.60 | $0.71 | | | View | N/A | |
| 2/23/2012 | | $0.55 | $0.72 | | | View | N/A | |
| 10/31/2011 | | $0.77 | $0.77 | | | View | N/A | |
| 7/28/2011 | | $0.61 | $0.70 | | | View | N/A | |
| 4/28/2011 | | $0.66 | $0.66 | | | View | N/A | |
| 2/24/2011 | | $0.73 | $0.80 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Integra LifeSciences Holdings Corporation (NASDAQ:IART)2017 EPS Consensus Estimate: $1.91
2018 EPS Consensus Estimate: $2.27
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 4 | $0.38 | $0.48 | $0.42 |
| Q2 2017 | 4 | $0.43 | $0.47 | $0.45 |
| Q3 2017 | 4 | $0.42 | $0.50 | $0.46 |
| Q4 2017 | 4 | $0.55 | $0.65 | $0.59 |
| Q1 2018 | 3 | $0.45 | $0.51 | $0.47 |
| Q2 2018 | 3 | $0.54 | $0.58 | $0.56 |
| Q3 2018 | 3 | $0.53 | $0.58 | $0.56 |
| Q4 2018 | 3 | $0.61 | $0.74 | $0.68 |
| Q1 2019 | 1 | $0.54 | $0.54 | $0.54 |
| Q2 2019 | 1 | $0.62 | $0.62 | $0.62 |
(Data provided by Zacks Investment Research)
Dividend History for Integra LifeSciences Holdings Corporation (NASDAQ:IART)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Integra LifeSciences Holdings Corporation (NASDAQ:IART)Insider Ownership Percentage: 21.50%
Institutional Ownership Percentage: 84.90%
Insider Trades by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/4/2017 | Donald E Morel Jr | Director | Buy | 10,000 | $49.25 | $492,500.00 | |
| 8/3/2017 | Donald E Morel Jr | Director | Buy | 2,500 | $49.29 | $123,225.00 | |
| 8/1/2017 | Barbara B Hill | Director | Buy | 5,050 | $49.33 | $249,116.50 | |
| 5/25/2017 | Stuart Essig | Director | Sell | 135,000 | $49.90 | $6,736,500.00 | |
| 5/23/2017 | Stuart Essig | Director | Sell | 140,000 | $48.01 | $6,721,400.00 | |
| 5/4/2017 | Glenn Coleman | VP | Sell | 13,865 | $45.91 | $636,542.15 | |
| 5/4/2017 | James M Sullivan | Director | Sell | 15,658 | $45.89 | $718,545.62 | |
| 11/8/2016 | Peter J Arduini | CEO | Sell | 24,009 | $79.51 | $1,908,955.59 | |
| 8/23/2016 | Raymond G Murphy | Director | Sell | 2,600 | $86.64 | $225,264.00 | |
| 8/9/2016 | Peter J Arduini | CEO | Sell | 24,009 | $84.52 | $2,029,240.68 | |
| 8/4/2016 | Raymond G Murphy | Director | Sell | 2,610 | $84.83 | $221,406.30 | |
| 8/1/2016 | Richard D Gorelick | VP | Sell | 4,000 | $84.60 | $338,400.00 | |
| 5/9/2016 | Joseph Vinhais | VP | Sell | 972 | $73.36 | $71,305.92 | |
| 5/4/2016 | Glenn Coleman | CFO | Sell | 3,563 | $70.62 | $251,619.06 | |
| 5/3/2016 | Christian S Schade | Director | Sell | 7,829 | $70.42 | $551,318.18 | |
| 5/2/2016 | Daniel L Reuvers | VP | Sell | 1,000 | $71.43 | $71,430.00 | |
| 4/29/2016 | Richard D Gorelick | VP | Sell | 4,000 | $70.72 | $282,880.00 | |
| 4/27/2016 | Stuart Essig | Director | Sell | 104,390 | $70.15 | $7,322,958.50 | |
| 4/6/2016 | Stuart Essig | Director | Sell | 21,100 | $66.19 | $1,396,609.00 | |
| 4/5/2016 | Stuart Essig | Director | Sell | 83,290 | $66.68 | $5,553,777.20 | |
| 4/4/2016 | Stuart Essig | Director | Sell | 42,150 | $67.26 | $2,835,009.00 | |
| 5/7/2015 | Stuart Essig | Director | Sell | 75,000 | $64.32 | $4,824,000.00 | |
| 5/6/2015 | Stuart Essig | Director | Sell | 125,000 | $64.83 | $8,103,750.00 | |
| 1/2/2015 | Judith Ogrady | VP | Sell | 3,500 | $53.33 | $186,655.00 | |
| 10/28/2014 | Stuart Essig | Director | Sell | 147,098 | $49.58 | $7,293,118.84 | |
| 10/27/2014 | Stuart Essig | Director | Sell | 41,268 | $49.56 | $2,045,242.08 | |
| 9/2/2014 | Judith Ogrady | VP | Sell | 2,500 | $49.82 | $124,550.00 | |
| 8/27/2014 | Richard D Gorelick | VP | Sell | 7,000 | $50.03 | $350,210.00 | |
| 8/25/2014 | John B Henneman III | CAO | Sell | 20,000 | $50.12 | $1,002,400.00 | |
| 8/22/2014 | Deborah A Leonetti | VP | Sell | 1,000 | $50.96 | $50,960.00 | |
| 8/8/2014 | Brian Larkin | VP | Sell | 1,947 | $48.28 | $94,001.16 | |
| 7/30/2014 | Stuart Essig | Director | Sell | 50,800 | $47.76 | $2,426,208.00 | |
| 7/23/2014 | Stuart Essig | Director | Sell | 27,819 | $47.80 | $1,329,748.20 | |
| 7/1/2014 | Judith Ogrady | VP | Sell | 2,500 | $47.54 | $118,850.00 | |
| 6/23/2014 | Stuart Essig | Director | Sell | 21,381 | $47.76 | $1,021,156.56 | |
| 4/3/2014 | Stuart Essig | Director | Sell | 6,344 | $46.01 | $291,887.44 | |
| 4/2/2014 | Stuart Essig | Director | Sell | 76,177 | $46.05 | $3,507,950.85 | |
| 3/31/2014 | Stuart Essig | Director | Sell | 17,479 | $46.05 | $804,907.95 | |
| 3/10/2014 | Deborah Leonetti | VP | Sell | 7,563 | $49.22 | $372,250.86 | |
| 3/4/2014 | Richard Gorelick | VP | Sell | 2,000 | $47.98 | $95,960.00 | |
| 2/28/2014 | Christian Schade | Director | Sell | 7,500 | $47.06 | $352,950.00 | |
| 2/27/2014 | Brian Larkin | VP | Sell | 3,265 | $46.15 | $150,679.75 | |
| 2/27/2014 | John Henneman III | CFO | Sell | 5,000 | $46.07 | $230,350.00 | |
| 1/16/2014 | Stuart Essig | Director | Sell | 8,037 | $49.59 | $398,554.83 | |
| 1/14/2014 | Stuart Essig | Director | Sell | 10,600 | $49.50 | $524,700.00 | |
| 1/13/2014 | Stuart Essig | Director | Sell | 99,032 | $49.51 | $4,903,074.32 | |
| 1/9/2014 | Stuart Essig | Director | Sell | 114,431 | $49.58 | $5,673,488.98 | |
| 8/30/2013 | Richard Gorelick | VP | Sell | 3,000 | $40.79 | $122,370.00 | |
| 8/23/2013 | Deborah Leonetti | VP | Sell | 8,906 | $41.68 | $371,202.08 | |
| 8/19/2013 | Brian Larkin | VP | Sell | 7,490 | $41.90 | $313,831.00 | |
| 8/19/2013 | John Henneman III | CFO | Sell | 30,000 | $42.08 | $1,262,400.00 | |
| 8/1/2013 | Judith Ogrady | VP | Sell | 1,000 | $39.50 | $39,500.00 | |
| 7/30/2013 | Judith Ogrady | VP | Sell | 2,000 | $38.50 | $77,000.00 | |
| 5/31/2013 | Jerry E Corbin | VP | Sell | 1,876 | $38.07 | $71,419.32 | |
(Data available from 1/1/2013 forward)
Headline Trends for Integra LifeSciences Holdings Corporation (NASDAQ:IART)
Latest Headlines for Integra LifeSciences Holdings Corporation (NASDAQ:IART)
| Source: |
|
| Date | Headline |
|---|
 | Integra LifeSciences Holdings Corporation (IART) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - October 19 at 4:46 AM |
| Integra LifeSciences Holdings Corporation to Post Q3 2017 Earnings of $0.45 Per Share, Northcoast Research Forecasts (IART)
www.americanbankingnews.com - October 16 at 2:14 AM |
| Integra LifeSciences Holdings Corporation's (IART) "Buy" Rating Reaffirmed at Jefferies Group LLC
www.americanbankingnews.com - October 15 at 5:50 PM |
 | Integra LifeSciences to Host Third Quarter 2017 Earnings Results Conference ...
www.nasdaq.com - October 12 at 6:11 AM |
 | Integra LifeSciences to Host Third Quarter 2017 Earnings Results Conference Call on October 26, 2017
finance.yahoo.com - October 12 at 6:11 AM |
| Integra LifeSciences Holdings Corporation (IART) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - October 10 at 4:34 PM |
| Integra's (IART) Revize/Revize-X Boosts Tissue Technology Arm
finance.yahoo.com - October 10 at 12:46 AM |
| Integra LifeSciences Holdings Corporation (IART) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - October 9 at 1:22 PM |
| Integra LifeSciences launches Revize™/ Revize™-X Collagen Matrix for Plastic and Reconstructive Surgery
finance.yahoo.com - October 6 at 8:09 PM |
| Integra LifeSciences' SurgiMend PRS Meshed Boosts ADM Line
finance.yahoo.com - October 5 at 11:10 AM |
| Analysts Expect Integra LifeSciences Holdings Corporation (IART) Will Post Quarterly Sales of $286.77 Million
www.americanbankingnews.com - October 5 at 10:36 AM |
| Integra LifeSciences launches SurgiMend® PRS Meshed Collagen Matrix for Plastic and Reconstructive Surgery
finance.yahoo.com - October 4 at 4:01 PM |
| Integra LifeSciences Holdings Corp. breached its 50 day moving average in a Bearish Manner : IART-US : October 4, 2017
finance.yahoo.com - October 4 at 4:01 PM |
| Integra LifeSciences' SurgiMend PRS Meshed Boosts ADM Line
finance.yahoo.com - October 4 at 4:01 PM |
| Integra LifeSciences Launches Integra® SurgiMend™ PRS Meshed Collagen Matrix for Breast Reconstruction in Europe
finance.yahoo.com - October 3 at 9:52 AM |
| Integra LifeSciences Launches Integra® SurgiMend(TM) PRS Meshed Collagen Matrix for Breast Reconstruction in Europe
finance.yahoo.com - October 3 at 9:52 AM |
| Integra LifeSciences Completes the Acquisition of Codman Neurosurgery Business from Johnson & Johnson
finance.yahoo.com - October 2 at 6:33 PM |
| Integra LifeSciences Holdings Corporation (IART) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 30 at 3:08 PM |
 | FTC allows Integra to buy J&J’s Codman neuro business, with conditions
www.reuters.com - September 28 at 3:44 PM |
| BRIEF-Integra lifesciences reports preliminary assessment of damage to Puerto Rico facility
www.reuters.com - September 26 at 10:45 AM |
 | Form 8-K INTEGRA LIFESCIENCES For: Sep 26
www.streetinsider.com - September 26 at 10:45 AM |
| Integra LifeSciences Announces First Patient Enrolled in Cadence® Total Ankle System Post-Market Study
finance.yahoo.com - September 22 at 2:13 PM |
| Integra LifeSciences Holdings Corp. – Value Analysis (NASDAQ:IART) : September 21, 2017
finance.yahoo.com - September 22 at 2:13 PM |
| Integra LifeSciences Holdings Corp. breached its 50 day moving average in a Bearish Manner : IART-US : September 20, 2017
finance.yahoo.com - September 20 at 4:03 PM |
| Integra LifeSciences Holdings Corporation (IART) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 18 at 8:58 PM |
| $286.37 Million in Sales Expected for Integra LifeSciences Holdings Corporation (IART) This Quarter
www.americanbankingnews.com - September 16 at 7:44 AM |
| Financial Comparison: Integra LifeSciences Holdings Corporation (IART) versus Sientra (SIEN)
www.americanbankingnews.com - September 16 at 12:10 AM |
 | Integra LifeSciences Holdings' (IART) CEO Peter Arduini Presents at Morgan Stanley Healthcare Conference (Transcript)
seekingalpha.com - September 13 at 1:02 AM |
| Integra LifeSciences Holdings Corporation's (IART) "Equal Weight" Rating Reiterated at Barclays PLC
www.americanbankingnews.com - September 12 at 4:30 PM |
 | Integra LifeSciences To Sell Certain Neurosurgery Assets To Natus Medical
www.rttnews.com - September 11 at 8:12 PM |
| Natus to Acquire Neurosurgery Assets from Integra LifeSciences, Enters Neurosurgery Market
finance.yahoo.com - September 11 at 8:11 PM |
| Integra LifeSciences Announces Definitive Agreement to Sell Certain Neurosurgery Assets to Natus Medical Incorporated
finance.yahoo.com - September 11 at 8:11 PM |
| Integra LifeSciences Holdings Corporation (IART) Earns Buy Rating from Jefferies Group LLC
www.americanbankingnews.com - September 10 at 6:24 AM |
| $286.10 Million in Sales Expected for Integra LifeSciences Holdings Corporation (IART) This Quarter
www.americanbankingnews.com - August 29 at 11:42 AM |
| ETFs with exposure to Integra LifeSciences Holdings Corp. : August 24, 2017
finance.yahoo.com - August 25 at 6:54 AM |
| Reviewing Integra LifeSciences Holdings Corporation (IART) and ICU Medical (ICUI)
www.americanbankingnews.com - August 18 at 10:18 PM |
| Integra LifeSciences to Present at Healthcare Conferences in September 2017
finance.yahoo.com - August 18 at 5:01 AM |
| Integra’s DuraSeal® dural sealant saves healthcare costs according to a study recently published in the Journal of Health Economics and Outcomes Research
finance.yahoo.com - August 11 at 8:11 PM |
| See what the IHS Markit Score report has to say about Integra Lifesciences Holdings Corp.
finance.yahoo.com - August 11 at 8:11 PM |
| ETFs with exposure to Integra LifeSciences Holdings Corp. : August 11, 2017
finance.yahoo.com - August 11 at 8:11 PM |
| Insider Buying: Integra LifeSciences Holdings Corporation (IART) Director Acquires 2,500 Shares of Stock
www.americanbankingnews.com - August 4 at 8:40 PM |
| Insider Buying: Integra LifeSciences Holdings Corporation (NASDAQ:IART) Director Buys 10,000 Shares of Stock
www.americanbankingnews.com - August 4 at 8:22 PM |
| Integra LifeSciences Holdings Corporation (IART) Director Purchases $249,116.50 in Stock
www.americanbankingnews.com - August 2 at 8:34 PM |
| Equities Analysts Set Expectations for Integra LifeSciences Holdings Corporation's FY2017 Earnings (IART)
www.americanbankingnews.com - August 2 at 10:38 AM |
| Integra LifeSciences Holdings Corporation Expected to Earn Q3 2017 Earnings of $0.46 Per Share (IART)
www.americanbankingnews.com - August 2 at 7:02 AM |
| Integra LifeSciences Holdings Enters Oversold Territory (IART)
www.nasdaq.com - August 2 at 1:22 AM |
| Q4 2017 EPS Estimates for Integra LifeSciences Holdings Corporation (IART) Lifted by Northcoast Research
www.americanbankingnews.com - August 1 at 11:57 AM |
| Integra LifeSciences Holdings Corp. :IART-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017
finance.yahoo.com - July 28 at 10:44 PM |
| Q3 2017 Earnings Estimate for Integra LifeSciences Holdings Corporation (IART) Issued By Jefferies Group
www.americanbankingnews.com - July 28 at 11:26 AM |
| Oppenheimer Holdings Weighs in on Integra LifeSciences Holdings Corporation's Q3 2017 Earnings (NASDAQ:IART)
www.americanbankingnews.com - July 28 at 11:26 AM |
Integra LifeSciences Holdings Corporation (IART) Chart for Thursday, October, 19, 2017
